Anthracycline-carboplatin combination in metastatic breast cancer.
In a pilot study a carboplatinu, 250 mg/m2 i.v., and 4-epidoxirubicin, 90 mg/m2 i.v. or mitoxantrone, 10 mg/m2 i.v., combination chemotherapy regimen was studied in a group of breast cancer patients with high-risk metastatic disease. All 11 patients had liver and/or lung metastases. Of the 11 patients, 9 had progressive disease and in 2 patients the disease had stabilised. The toxicity of both anthracycline-containing regimes was similar. Subjective toxicity was mild, but hematological toxicity was inacceptable. The tested carboplatinum-anthracycline combination regimes given in the administered doses are not useful in the treatment of metastatic breast cancer, mainly because of toxicity.
Thürlimann
B
B
Department of Internal Medicine, Kantonsspital, St Gallen, Switzerland.
Senn
H J
HJ
Jungi
W F
WF
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D016190:Carboplatin; D015251:Epirubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008875:Middle Aged; D008942:Mitoxantrone / Q000008:administration & dosage; D009362:Neoplasm Metastasis; D009944:Organoplatinum Compounds / Q000008:administration & dosage
D009944:Organoplatinum Compounds; D015251:Epirubicin; D016190:Carboplatin; D008942:Mitoxantrone